Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 310

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Open access
Afkhami, Sam, D’Agostino, Michael R., Zhang, Ali, Stacey, Hannah D., Marzok, Art, Kang, Alisha, Singh, Ramandeep, Bavananthasivam, Jegarubee, Ye, Gluke, Luo, Xiangqian, Wang, Fuan, Ang, Jann C., Zganiacz, Anna, Sankar, Uma, Kazhdan, Natallia, Koenig, Joshua F.E., Phelps, Allyssa, Gameiro, Steven F., Tang, Shangguo, Jordana, Manel, Wan, Yonghong, Mossman, Karen L., Jeyanathan, Mangalakumari, Gillgrass, Amy, Medina, Maria Fe C., Smaill, Fiona, Lichty, Brian D., Miller, Matthew S., Xing, Zhou·2022·Cell

Abstract

Summary The emerging SARS-CoV-2 variants of concern (VOC) increasingly threaten the effectiveness of current first-generation COVID-19 vaccines that are administered intramuscularly and are designed to only target the spike protein. There is thus a pressing need to develop next-generation vaccine strategies to provide more broad and long-lasting protection. By using adenoviral vectors (Ad) of human and chimpanzee origin, we developed Ad-vectored trivalent COVID-19 vaccines expressing Spike-1, Nucleocapsid and RdRp antigens and evaluated them following single-dose intramuscular or intranasal immunization in murine models. We show that respiratory mucosal immunization, particularly with chimpanzee Ad-vectored vaccine, is superior to intramuscular immunization in induction of the three-arm immunity, consisting of local and systemic antibody responses, mucosal tissue-resident memory T cells, and mucosal trained innate immunity. We further show that single-dose intranasal immunization provides robust protection against not only the ancestral strain of SARS-CoV-2, but also two emerging VOC, B.1.1.7 and B.1.351. Our findings indicate that single-dose respiratory mucosal delivery of an Ad-vectored multivalent vaccine represents an effective next-generation COVID-19 vaccine strategy against current and future VOC. This strategy has great potential to be used not only to boost first-generation vaccine-induced immunity but also to expand the breadth of protective T cell immunity at the respiratory mucosa.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2022.02.005

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 310

Metadata

Authors
Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., Wang, F., Ang, J. C., Zganiacz, A., Sankar, U., Kazhdan, N., Koenig, J. F. E., Phelps, A., Gameiro, S. F., Tang, S., Jordana, M., Wan, Y., Mossman, K. L., Jeyanathan, M., Gillgrass, A., Medina, M. F. C., Smaill, F., Lichty, B. D., Miller, M. S., & Xing, Z.
Venue
Cell
Publisher
Elsevier BV
Published
2022-03
Volume
185
Issue
5
Pages
896-915.e19
ISSN
0092-8674 (ISSN-L)
OpenAlex
W4210888864
Cited by
310
References
82
FWCI
32.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. https://app.cochat.ai/papers/10.1016/j.cell.2022.02.005
The paper
Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., Wang, F., Ang, J. C., Zganiacz, A., Sankar, U., Kazhdan, N., Koenig, J. F. E., Phelps, A., Gameiro, S. F., Tang, S., . . . Xing, Z. (2022). Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. https://doi.org/10.1016/j.cell.2022.02.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.